miR-205-5p-mediated downregulation of ErbB/HER receptors in breast cancer stem cells results in targeted therapy resistance

• DOI: 10.1038/cddis.2015.192
• Publication Date: 2015-07-16T12:48:04Z
• Authors: A De Cola; S Volpe; M C Budani; M Ferracin; R Lattanzio; A Turdo; D D'Agostino; E Capone; G Stassi; M Todaro; C Di Ilio; G Sala; M Piantelli; M Negrini; A Veronese; V De Laurenzi
• Keywords: ErbB; Targeted Therapy; ERBB3

Abstract The ErbB tyrosine kinase receptor family has been shown to have an important role in tumorigenesis, and the expression of its members is frequently deregulated many types solid tumors. Various drugs targeting these receptors approved for cancer treatment. Particularly, breast cancer, anti-Her2/EGFR molecules represent standard therapy Her2-positive malignancies. However, a number cases, tumor relapses or progresses thus suggesting that not all cells targeted. One possibility subset capable regenerating tumor, such as stem (CSCs), may respond therapeutic agents. Accumulating evidences indicate miR-205-5p significantly downregulated tumors compared with normal tissue acts suppressor directly oncogenes Zeb1 ErbB3. In this study, we report highly expressed BCSCs represses ERBB2 indirectly EGFR leading resistance targeted therapy. Furthermore, show regulates p63 which turn involved miR-205/p63/EGFR regulation.